Cyclofenil: Difference between revisions
(Created page with "<div style="float: right;"> thumb|none|400px|This image is provided by the National Library of Medicine.</div> __NOTOC__ {{SI}} {{CMG}} ==Overview...") |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="float: right;"> | <div style="float: right;"> | ||
[[File: | [[File:Cyclofenil.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Cyclofenil''' ([[International Nonproprietary Name|INN]], trade names '''Ondogyne''', '''Sexovid''', and others) is a [[selective estrogen receptor modulator]]. | '''Cyclofenil''' ([[International Nonproprietary Name|INN]], trade names '''Ondogyne''', '''Sexovid''', and others) is a [[selective estrogen receptor modulator]]. | ||
| Line 16: | Line 12: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 13:45, 7 April 2015
|
WikiDoc Resources for Cyclofenil |
|
Articles |
|---|
|
Most recent articles on Cyclofenil |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cyclofenil at Clinical Trials.gov Clinical Trials on Cyclofenil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cyclofenil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cyclofenil Discussion groups on Cyclofenil Patient Handouts on Cyclofenil Directions to Hospitals Treating Cyclofenil Risk calculators and risk factors for Cyclofenil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cyclofenil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cyclofenil (INN, trade names Ondogyne, Sexovid, and others) is a selective estrogen receptor modulator.
It was investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective.[1] Later study of its efficacy in treating Raynaud's phenomenon in people with scleroderma also found no statistically significant benefit.[2]
References
- ↑ Torres MA, Furst DE (February 1990). "Treatment of generalized systemic sclerosis". Rheum Dis Clin North Am. 16 (1): 217–41. PMID 2406809.
- ↑ Pope J, Fenlon D, Thompson A; et al. (2000). Pope, Janet, ed. "Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis". Cochrane Database Syst Rev (2): CD000955. doi:10.1002/14651858.CD000955. PMID 10796397.